Journal of clinical practice and research, cilt.45, sa.6, ss.605-613, 2023 (Hakemli Dergi)
Objective: Antimicrobial drugs are frequently used in the intensive care unit (ICU) and may
cause drug-drug interactions (DDIs) which change treatment outcomes. This study aims to
determine the frequency of potential DDIs (pDDIs) caused by antimicrobial drugs in the ICU,
according to two databases, address the differences between these two databases, discuss
the clinical significance of pDDIs and investigate their relationship with clinical outcomes.
Materials and Methods: This study was designed as a 1-year retrospective cross-sectional
study. Patients over the age of 18 who used antimicrobials for at least 72 hours were included. pDDIs between other drugs and antimicrobials were checked using the “drug interactions” modules of the Lexicomp and Micromedex databases. Data were collected from the
hospital’s records by a clinical pharmacist.
Results: A total of 393 drug profiles were evaluated for 100 patients, of which 84.2% were
antibacterial drugs. According to at least one database, 88% of patients had pDDIs. Of these,
62.4% were classified as major according to at least one database. Only 27.3% of pDDIs had
the same level of interaction in both databases. Common pDDIs posed risks such as additive
nephrotoxicity, excessive sedation, respiratory depression and QT interval prolongation.
Conclusion: pDDIs should be checked not only by one database but by multiple databases,
coupled with the input of an experienced clinical pharmacist.
Keywords: Antibacterial drug, antifungal drug, drug-drug interactions, intensive care, clinical pharmacy.